Nurse Practitioner Outlines CDK4/6 Inhibitor Toxicity in HR+ Breast Cancer

Commentary
Video

Fatigue and mouth sores are some of the common adverse effects associated with treatment using palbociclib or ribociclib, says Sarah Donahue, MPH, NP.

In addition to managing toxicities such as arthralgia, it is important to ensure that patients with hormone receptor–positive breast cancer are exercising often so that they can mitigate fatigue associated with CDK4/6 inhibitor treatment, including agents such as palbociclib (Ibrance) and ribociclib (Kisqali), said Sarah Donahue, MPH, NP.

In a conversation with CancerNetwork®, Donahue, a nurse practitioner at University of California, San Francisco, and part of the Oncology Nursing Society, also described the toxicity profile of abemaciclib (Verzenios) in the treatment of the aforementioned patient population. With abemaciclib, she stated that adverse effects like diarrhea could be managed with loperamide, if needed.

Transcript:

Palbociclib and ribociclib can both cause neutropenia. We’re giving patients 3-weeks-on, 1-week-off treatment for that reason, and we’re checking labs a lot. They can both cause fatigue, and they can both cause mouth sores. They’re always given with hormone therapy, so the [adverse] effects of the hormone therapy can be added on; usually it’s fulvestrant or an aromatase inhibitor. It may [cause] hot flashes if it’s the fulvestrant, or it might be arthralgia and hot flashes for aromatase inhibitors. They all come together. What I drive home with patients is that these are first-line therapies for [those with] hormone receptor–positive metastatic breast cancer.

We need to make sure that [patients are] active and exercising a lot. That really helps with the fatigue, and the arthralgia from the aromatase inhibitors. We make sure to treat their hot flashes, especially if they are leading to any sort of insomnia.

With abemaciclib, I’m generally not using that in the first line. It’s more of a second-line therapy that has more diarrhea with it and less of the decreased counts. Patients can take [abemaciclib] continuously without a break, so the labs don’t get affected as much. But the diarrhea can be pretty tough in the beginning for some patients, [so I] make sure that they’re using their loperamide as needed. Sometimes, I’m having them schedule it preventively, noting that they can take up to 8 tabs a day and that is expected and can easily be reduced if the loperamide is not working by doing things like dose reducing even just a little bit.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.